Drug name - Xerava
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10961190 | TETRAPHASE PHARMS | Crystalline forms of eravacycline |
Oct, 2037
(15 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8796245 | TETRAPHASE PHARMS | C7-fluoro substituted tetracycline compounds |
Aug, 2029
(6 years from now) | |
| US8906887 | TETRAPHASE PHARMS | C7-fluoro substituted tetracycline compounds |
Dec, 2030
(8 years from now) | |
Drugs and Companies using ERAVACYCLINE DIHYDROCHLORIDE ingredient
Treatment: Treatment of complicated intra-abdominal infections in patients 18 years of age and older
Dosage: POWDER;INTRAVENOUS
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 50MG BASE/VIAL | POWDER;INTRAVENOUS | Prescription |
| EQ 100MG BASE/VIAL | POWDER;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.